Breaking Finance News

BidaskClub downgraded Global Blood Therapeutics Inc (NASDAQ:GBT) to Sell in a report released today.

BidaskClub has downgraded Global Blood Therapeutics Inc (NASDAQ:GBT) to Sell in a report released on 06/20/2017.

Yesterday Global Blood Therapeutics Inc (NASDAQ:GBT) traded 6.06% higher at $28.45. The company’s 50-day moving average is $27.76 and its 200-day moving average is $30.02. The last closing price is down -6.74% from the 200-day moving average, compared to the S&P 500 which has increased 0.04% over the same time period. 1,684,553 shares of the stock traded hands, up from an average trading volume of 824,639

See Chart Below

Global Blood Therapeutics Inc (NASDAQ:GBT)

Global Blood Therapeutics Inc has a 52 week low of $13.35 and a 52 week high of $41.15 The company’s market cap is currently $0.

In addition to BidaskClub reporting its stock price target, a total of 4 brokers have issued a report on the company. The average stock price target is $59.75 with 0 brokers rating the stock a strong buy, 0 brokers rating the stock a buy, 0 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.

General Information About Global Blood Therapeutics Inc (NASDAQ:GBT)

Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD). The Company is evaluating GBT440 in SCD in a Phase III clinical trial of GBT440 in adult and adolescent patients with SCD. GBT440 inhibits abnormal hemoglobin polymerization, the underlying mechanism of RBC sickling. The Company is also engaged in other research and development activities targeted towards hereditary angioedema (HAE). The Company's GBT440 is an investigational drug that increases hemoglobin's affinity for oxygen by binding to the alpha-chain of hemoglobin. GBT440 has been observed to keep a proportion of sickle hemoglobin (HbS), in its oxygenated state, where it cannot participate in polymerization.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.